News from other sources...
The Western world's first gene therapy is soon to become but a footnote in biotech history, doomed by minuscule demand and a colossal price. But its failure has hardly dampened the enthusiasm of the scientists and biotech companies betting that gene therapy's best days are ahead.
What doesn't kill you can maim: unexpected injuries from opioids | Kaiser Health News
The trouble started for Lisa when she took a blood pressure pill and one to control seizures, along with methadone, a drug used to help wean patients off heroin.
With drug costs in cross hairs, health firms gave generously to Trump's inauguration | Kaiser Health News
Facing acute risks to their businesses from Washington policymakers, health companies spent more than $2 million to buy access to the incoming Trump administration via candlelight dinners, black-tie balls and other inauguration events, new filings show.
Canadian drugmaker Valeant Pharmaceuticals International Inc said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017.
For doctors, a clamp down on visas could have an uneven effect in the U.S. | Kaiser Health News
Limiting the number of foreign doctors who can get visas to practice in the United States could have a significant impact on certain hospitals and states that rely on them, according to a new study.
Safety, quality and clinical practice
Stalking the 'unknown enemy': Doctors turn scope on rare diseases | Kaiser Health News
Lynn Whittaker stood in the hallway of her home looking at the framed photos on the wall. In one, her son, Andrew, is playing high school water polo. In another, he's holding a trombone.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.